Welcome to our dedicated page for Olink Holding Ab (Publ) news (Ticker: OLK), a resource for investors and traders seeking the latest updates and insights on Olink Holding Ab (Publ) stock.
About Olink Holding AB (publ)
Olink Holding AB (publ) (Nasdaq: OLK) is a biotechnology company specializing in advancing proteomics research to enable groundbreaking discoveries and improve patient outcomes. Founded in 2016 and headquartered in Uppsala, Sweden, the company operates globally, with a presence across Europe, North America, and Asia. Olink’s innovative platform is designed to deepen the understanding of real-time human biology, empowering researchers to address complex biological questions and drive the development of 21st-century healthcare solutions.
Core Business and Value Proposition
Olink provides a comprehensive platform of products and services tailored for proteomics research. This platform is widely adopted by leading biopharmaceutical companies, clinical research organizations, and academic institutions. By integrating advanced proteomics technologies with data-driven insights, Olink enables its customers to explore protein expression, interactions, and functions across multiple disease areas. The company’s offerings are instrumental in advancing precision medicine, biomarker discovery, and translational research.
Revenue Model and Market Presence
Olink’s business model combines product sales, consumables, and services, creating a hybrid revenue stream. The company’s instruments and consumables are essential for conducting proteomics experiments, while its data analysis services provide actionable insights. This recurring revenue model positions Olink as a key partner for organizations aiming to accelerate their research workflows. With a strong foothold in the proteomics market, Olink serves as a bridge between cutting-edge science and practical healthcare applications.
Industry Context and Competitive Landscape
The proteomics industry is a rapidly growing segment within biotechnology, driven by the increasing demand for precision medicine and personalized healthcare. Olink operates at the forefront of this industry, leveraging its proprietary technologies to deliver high-throughput, high-precision proteomics solutions. The company differentiates itself through its ability to provide scalable and actionable data, addressing the needs of both commercial and academic researchers. While the industry presents challenges such as high R&D costs and regulatory hurdles, Olink’s innovative approach and global reach position it as a significant player in the market.
Significance and Impact
Olink’s contributions to the scientific community extend beyond its products and services. By enabling researchers to gain deeper insights into protein biology, the company plays a crucial role in advancing our understanding of complex diseases, identifying novel therapeutic targets, and improving patient care. Its platform has become a cornerstone for institutions aiming to bridge the gap between research and clinical application, making Olink a pivotal entity in the evolution of modern healthcare.
Olink Holding AB will hold its Annual General Meeting on April 17, 2023, at 4:00 p.m. CET in Uppsala, Sweden. Shareholders must be registered by April 5, 2023, and notify the company by April 11, 2023, to participate. The agenda includes the election of board members, presentation of financial reports, and resolutions for incentive programs LTI I 2023 and LTI II 2023. The Nomination Committee proposes Jon Hindar as Chairman and nine board members total. Shareholders can also authorize proxies to vote on their behalf. Notably, the proposed incentive programs involve stock options and warrants, aimed at boosting management engagement and aligning interests with shareholders.
iuno has officially launched its Beta program, introducing a pioneering approach to skincare through proteomics. The program allows individuals to undergo an at-home finger prick test to analyze their unique protein composition, leading to customized skincare solutions. Partnering with Olink (NASDAQ-NMS:OLK), iuno creates personalized skincare regimens based on a user's specific needs derived from protein analysis. For $99, participants receive a skin primer kit alongside their proteomic report, with further personalized options available for $249 and $299. This innovative model aims to address 83% of skin issues linked to blood proteins.
Olink Holding AB (Nasdaq: OLK) announced the opening of the NUS Medicine Protein Biomarker Discovery Core Facility at the Yong Loo Lin School of Medicine, National University of Singapore on March 6, 2023. This facility will utilize Olink's advanced proteomics technology, including Explore and Target platforms, enhancing research in protein biomarkers. It aims to facilitate population health studies and support local and global researchers in disease understanding and drug development. The collaboration signifies Olink’s commitment to advancing scientific research in the Asia Pacific region, leveraging Singapore's diverse population for better health outcomes.
Olink Holding AB (Nasdaq: OLK) has entered into a significant agreement with the Regeneron Genetics Center (RGC) to enhance the use of Olink's High-Plex proteomics offerings. This collaboration seeks to combine RGC’s genomics expertise with Olink's proteomic capabilities, aiming to generate large-scale proteomic data. This integration is designed to improve understanding of complex diseases and facilitate the discovery of new biomarkers and therapeutic targets, ultimately advancing precision medicine. RGC anticipates that utilizing the Olink Explore platform will yield deeper insights into disease biology, supporting drug discovery efforts.
Olink Holding AB (Nasdaq: OLK) reported strong financial results for Q4 and full year 2022. Q4 revenue reached $57.9 million, a 33% increase year-over-year, while full-year revenue totaled $139.8 million, up 47%. The company achieved significant growth with Explore installations reaching 52 and Signature Q100 placements at 91. Net income for Q4 was $5.4 million, a turnaround from a net loss of ($8.0 million) in Q4 2021. Looking ahead, Olink expects full-year 2023 revenue between $192 million and $200 million, reflecting continued growth momentum.
Olink Holding AB (Nasdaq: OLK) has announced a public offering of 5,831,028 American Depositary Shares (ADSs) at $20.00 each. The offering includes 4,250,000 ADSs from Olink and 1,581,028 ADSs from selling shareholders. A 30-day option to purchase an additional 874,654 ADSs has been granted to underwriters. The offering is anticipated to close around January 23, 2023. Olink will not receive proceeds from the sale of ADSs by selling shareholders. The underwriters for this offering include Goldman Sachs and J.P. Morgan. The registration statement for these securities became effective on January 18, 2023.
Olink Holding AB (publ) (Nasdaq: OLK) announced a public offering of 5,831,028 American Depositary Shares (ADSs), comprising 4,250,000 ADSs from the company and 1,581,028 from selling shareholders. The underwriters will have a 30-day option to purchase an additional 874,654 ADSs. The Company will not receive proceeds from the selling shareholders' ADSs. Goldman Sachs Bank Europe SE and J.P. Morgan Securities LLC lead the offering. The offering is subject to market conditions and may vary in size and terms. Olink provides a proteomics platform for scientific discovery and healthcare advancements.
Olink Holding AB (Nasdaq: OLK) announced preliminary unaudited revenues for Q4 and FY 2022, projecting full-year revenues between $139.4 million and $139.8 million, marking a 47% increase year-over-year. Q4 revenues are expected to reach $57.5 million to $57.9 million, a rise from $43.7 million in Q4 2021. Olink anticipates 2023 revenues of $192 million to $200 million, indicating growth of 37% to 43%. The company aims to return to profitability in 2023, driven by strong operational execution and innovative product development.
Olink Holding AB (Nasdaq: OLK) is set to participate in the 41st Annual JP Morgan Healthcare Conference on January 11, 2023, at 7:30 am PT. During this event, company management will present insights into Olink's commitment to advancing proteomics in collaboration with the scientific community. A live and archived webcast of the presentation will be accessible via the Company’s website. Founded in 2016, Olink is focused on enhancing understanding of human biology and supporting healthcare innovations.
Discovery Life Sciences has launched a new Proteomic Services Division, accepting samples from various research entities to enhance drug and diagnostic development. This division integrates cutting-edge technologies, including the Seer Proteograph Product Suite and SCIEX LC-MS/MS systems. Discovery has formed a Proteogenomics Consortium with Seer and SCIEX to advance plasma proteomic studies, aimed at uncovering novel biomarkers. The company also highlighted its status as the largest certified provider for Olink's Proximity Extension Assay platform in the Americas.
FAQ
What is the current stock price of Olink Holding Ab (Publ) (OLK)?
What is the market cap of Olink Holding Ab (Publ) (OLK)?
What does Olink Holding AB (publ) specialize in?
Who are Olink’s primary customers?
How does Olink generate revenue?
What makes Olink unique in the proteomics industry?
What role does Olink play in precision medicine?
Where is Olink headquartered?
What industries does Olink primarily serve?
What challenges does Olink face in its industry?
How does Olink contribute to healthcare innovation?
What is proteomics, and why is it important?
